Drugs / Contrave
Contrave
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CONTRAVE | — | 2014-09-10 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04499950 | Feb 2021 → Jan 2024 | breast cancer, obesity disorder | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03431831 | Jul 2017 → Jun 2022 | obesity disorder | University of Nebraska | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05812183 Background | Jul 2023 → Feb 2025 | — | University of California, Los Angeles | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Contrave | “Naltrexone-bupropion (Contrave)” NCT05812183 ↗ |
| Known as | Naltrexone-bupropion | “Naltrexone-bupropion (Contrave)” NCT05812183 ↗ |
| Known as | naltrexone-buproprion | “In the group with pharmacotherapy added to the MI, the naltrexone-buproprion (Contrave) protocol will be added to the patients intervention.” NCT03431831 ↗ |
| Route | Oral | “Orally” NCT03431831 ↗ |